The purpose of this study is to evaluate the effectiveness of an experimental drug called selinexor in children and young adults who have been diagnosed with high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). A glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high-risk (or high-grade) when it is growing and spreading quickly. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). The study aims to find the highest dose of selinexor that can be safely given with radiation therapy (Part 1 of the study, which has been completed). Researchers also want to determine the effects that selinexor has on people with HGG, DMG or DIPG and whether it is a beneficial treatment for the patient’s tumor (Part 2). In Part 2, participants will receive the maximum tolerated dose of selinexor. If the patient experiences negative side effects, the dose may be decreased.
What is the full name of this clinical trial?
ACNS1821 A Phase 1/2 Trial of Selinexor and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma